GlaxoSmithkline - Broker downgrade wipes £1.4bn from the value of Europe's largest drug maker
Citi has gone to ‘neutral’ from ‘buy’ on GSK shares, which it reckons are worth £17 each
Company
AstraZeneca PLC
LON:AZN
AstraZeneca is one of the world's leading pharmaceutical companies, with a broad range of medicines designed to fight disease. AstraZeneca has over 67,000 empolyees and operates in over 100 countries with growing presence in important emerging markets.
1084 stories · page 42 of 55
GlaxoSmithKline and AstraZeneca among drug stocks buoyed by Trump’s healthcare plans
The Republicans are looking to repeal Obamacare as well as trying to ease regulatory pressures in the industry
FTSE 100 ends lower as May makes offer for EU nationals
The UK blue chip index closed down around 15 points at 7,424
Clovis Oncology to raise US$250mln to build on ovarian cancer trial success
Rubraca is one of a new type of cancer treatment called PARP-inhibitors
Archive
The Rookie Investor: Learning not to get caught in the value trap
Sometimes a cheap stock is cheap for a reason, not just because it’s good value…
Liberum Capital downgrades European pharma sector to 'neutral', but remains positive on GlaxoSmithKline and AstraZeneca
The broker has been bullish on the sector since November’s US elections, in which time the sector has advanced 20%, or 12% in relative terms.
FTSE 100 closes lower as Britain heads to the polls
The blue chip FTSE 100 index closed 28 points down at 7,449
AstraZeneca raises initial US$200mln from sale of global rights to its Zomig treatment for migraines and cluster headaches
The Swiss firm will pay AstraZeneca US$200mln upon completion of the deal, and AstraZeneca will also receive up to an additional $102mln in future milestone payments
Investments and investor services
FTSE 100 closes below 7,500 ahead of UK election
FTSE 100 closed below the 7,500 level as traders sit and wait it out..
ASCO 2017: AstraZeneca’s breast cancer treatment leads the way
There were also promising readouts from a prostate cancer trial and an early-stage ovarian cancer study
AstraZeneca’s Lynparza breast cancer drug impresses in phase III trial
The results bode well for Astra, which is looking to build a successful oncology franchise
Archive
It's all (about) the election stupid
Election to dominate as polls suggest a turbulent week ahead while cancer forum will put spotlight on pharma
AstraZeneca PLC 'one for the brave', but still a 'buy', according to leading City broker
“It would be easy to downgrade Astra here,” said analyst Roger Franklin.
Synairgen pleased with the progress made with the LOXL2 programme
The company is pleased with the progress made with the LOXL2 programme and clearly is not giving up on its IFN-beta candidate
Lung cancer success means AstraZeneca now has a “significant lead” over competitors
That’s according to Deutsche Bank, but analysts at HSBC aren’t quite so sure
Nasdaq puts S&P 500 and Dow in the shade - again
It's a case of "in for a Penney, in for a pounding" today
AstraZeneca, Merck and Bristol-Myers vying for dominance in lung cancer market
Merck seems to be ahead in the race to develop the number one lung cancer treatment, but for how long?
AstraZeneca reports “highly encouraging” initial results from its PACIFIC lung cancer trial
It bodes well for the upcoming readout of the MYSTIC trial which is what investors and the markets are really waiting for
FTSE 100 closes at record high after third-straight week of gains
At the close, the UK blue chip index was up 0.7%, or 48.8 points at 7,435.4, not far below its all-time record of 7,447.0
Investments and investor services
FTSE 100 finishes little changed after "Super Thursday" underwhelms
The Footsie was back in black - but only just - thanks to precious metals miners